CODX vs. TMDIF, APT, CTSO, SPAI, APYX, INO, MBOT, CLGN, DXR, and OM
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include Titan Medical (TMDIF), Alpha Pro Tech (APT), Cytosorbents (CTSO), Safe Pro Group Inc. Common Stock (SPAI), Apyx Medical (APYX), Inovio Pharmaceuticals (INO), Microbot Medical (MBOT), CollPlant Biotechnologies (CLGN), Daxor (DXR), and Outset Medical (OM). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs.
Titan Medical (NASDAQ:TMDIF) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
In the previous week, Co-Diagnostics had 5 more articles in the media than Titan Medical. MarketBeat recorded 5 mentions for Co-Diagnostics and 0 mentions for Titan Medical. Co-Diagnostics' average media sentiment score of 0.29 beat Titan Medical's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.
0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 6.1% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Titan Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.
Titan Medical has a net margin of 0.00% compared to Co-Diagnostics' net margin of -563.93%. Co-Diagnostics' return on equity of -54.94% beat Titan Medical's return on equity.
Titan Medical has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.
Co-Diagnostics has a consensus price target of $1.50, suggesting a potential upside of 200.36%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Titan Medical.
Co-Diagnostics received 273 more outperform votes than Titan Medical when rated by MarketBeat users.
Summary
Co-Diagnostics beats Titan Medical on 11 of the 16 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 3/12/2025 by MarketBeat.com Staff
Free CODX Stock Alerts